Hannah Linden, MD, FACP

Hannah Linden, MD, FACP

Education

Yale University, 1985, BA cum laude
University of Massachusetts, 1989, MD
University of Arizona Medical Center, 1989-1992, Residency
University of Arizona Medical Center, 1992-1993, Fellowship, Pharmacology
University of Washington School of Medicine, 1993-1994, Fellowship, Hematology
University of Washington, 1994-2002, Senior Research Fellow in Hematology

Research Focus

  • Understanding resistance and sensitivity to endocrine therapy of breast cancer, and identification of methods to overcome resistance
  • Pharmacodynamic imaging
  • Improving access to clinical trials
  • Improving outcomes for vulnerable populations

Clinical Expertise

  • Endocrine treatment of breast cancer
  • Investigational breast cancer clinical treatments
  • Molecular imaging
  • Improving care of vulnerable populations

Current Studies

Advanced PET-CT Imaging for Improving Clinical Trials
Funding Source: NCI/NIH
The goal is to improve cancer clinical trials by enhancing the effectiveness of quantitative PET/CT imaging of tumor response.

A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy
Funding Source: Merck & Co
The primary aim is to determine the rate of clinical benefit for patients treated with cyclic two week vorinostat followed by resumption of AI therapy.

An Open-Label, Phase I Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Funding Source: Genentech, Inc.
The primary objective is to determine the maximum tolerated dose and/or recommended Phase II dose and assess the safety of ARN-810 in postmenopausal women with locally advanced or metastatic ER+ (HER2-) breast cancer.

Efficacy of Palonosetron in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting Following Dose Dense Adriamycin-Cyclophosphamide Chemotherapy in Early Stage Breast Cancer Patients
Funding Source: Eisai, Inc.
The primary objective is that a proportion of patients achieve a complete response defined as no emesis and no rescue medications in the 0-24 hour time period following weekly intravenous doxorubicin.

Phase II Study of Vitamin D Deficiency and Myalgias/Arthralgias Associated with Letrozole (Femara)
Funding Source: Novartis Pharmaceuticals Corporation
The primary objective is to confirm presence of vitamin D deficiency in patients who experience arthralgias and/or myalgias associated with letrozole therapy.

Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)
Funding Source: Eisai Inc.
We believe that the optimal schedule of eribulin has yet to be defined and that an approach similar to that used with vinorelbine could improve the tolerability of the agent without sacrificing efficacy. A lower dose metronomic schedule would allow responding patients to remain on treatment resulting in a longer time to progression and greater use of the drug in practice.

A Phase II Randomized, Double-Blind Placebo Controlled Study of Letrozole with or without BYL719 or Buparlisib for the Neoadjuvant Treatment of Postmenopausal Women with Hormone Receptor-Positive HER2-Negative Breast Cancer
Funding Source: Novartis Pharmaceuticals Corporation
The primary objective is to assess the anti-tumor activity of BYL719 QD plus letrozole and buparlisib QD plus letrozole versus letrozole alone in increasing the pathologic complete response rate during neoadjuvant treatment among postmenopausal patients with HR+, HER2-negative breast cancer for each of the two cohorts i) PIK3CA mutated and ii) PIK3CA wild tumor types.

EAI142 – [18F] Fluoroestradiol (FES) as a Predictive Measure for Endocrine Therapy in Women with Newly Diagnosed Metastatic Breast Cancer
Funding Source: ECOG-ACRIN Medical Research Foundation, Inc.
The purpose is to provide funding for Dr. Linden’s Scope of Work for this trial which is to ensure 1) the protocol scientific aims are consistent with scientific strategy of the related disease site as determined by each disease site committee and 2) compliance with the protocol. She will coordinate with the protocol team to oversee the study conduct and address questions from sites concerning protocol eligibility.

A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating the Efficacy and Safety of GTx-024 on Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Funding Source: GTx Inc.
The primary efficacy objective of this trial is to estimate the clinical benefit rate at 24 weeks of GTx-024 9 mg and of GTx-024 18 mg given PO daily in subjects with ER+/AR+ breast cancer who have centrally confirmed AR+ status.

A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating the Efficacy and Safety of GTx-024 on Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women
Funding Source: GTx Inc.
The primary efficacy objective of this trial is to estimate the clinical benefit rate at 24 weeks of GTx-024 9 mg and of GTx-024 18 mg given PO daily in subjects with ER+/AR+ breast cancer who have centrally confirmed AR+ status.

A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast.
Funding Source: Sanofi-Aventis U.S.
Primary objective Dose escalation: PART A (SAR439859 monotherapy); PART C (combination of SAR439859 with palbociclib)

  • To assess the incidence rate of dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) as well as the recommended dose (RD) of SAR439859 administered as monotherapy (Part A), then in combination with palbociclib (Part C), to postmenopausal women with estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Dose expansion: PART B (SAR439859 monotherapy); PART D (combination SAR439859 with palbociclib)
  • To assess antitumor activity using objective response rate (ORR) according to response evaluation criteria in solid tumors (RECIST) v1.1 at the SAR439859 RD administered as monotherapy (Part B), then in combination with palbociclib (Part D), to postmenopausal women with ER-positive and HER2-negative advanced breast cancer.


Hannah Linden, MD, FACP

Contact Information

Phone
(206) 606-2053
Fax
(206) 606-2023
Email
Additional contact

Administrative Contact:
Michele Roe

MailStop: G3630